Stable reporter cell lines for peroxisome proliferator-activated receptor γ (PPARγ)-mediated modulation of gene expression.

[1]  A. Jungbauer,et al.  Culinary plants, herbs and spices – A rich source of PPARγ ligands , 2009 .

[2]  F. Ondrey,et al.  Peroxisome Proliferator-Activated Receptor γ Pathway Targeting in Carcinogenesis: Implications for Chemoprevention , 2009, Clinical Cancer Research.

[3]  T. Kanda,et al.  Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: are the reagents beneficial or harmful? , 2008, International journal of cardiology.

[4]  L. Nagy,et al.  The many faces of PPARgamma: anti-inflammatory by any means? , 2008, Immunobiology.

[5]  D. Goldenberg,et al.  Potential of Peroxisome Proliferator-Activated Receptor Gamma Antagonist Compounds as Therapeutic Agents for a Wide Range of Cancer Types , 2008, PPAR research.

[6]  G. Landreth,et al.  PPARγ agonists as therapeutics for the treatment of Alzheimer’s disease , 2008, Neurotherapeutics.

[7]  H. Chung,et al.  Molecular mechanism of PPAR in the regulation of age-related inflammation , 2008, Ageing Research Reviews.

[8]  G. McVeigh,et al.  Thiazolidinediones: effects on insulin resistance and the cardiovascular system , 2008, British journal of pharmacology.

[9]  M. Kilgore,et al.  PPARγ1 as a Molecular Target of Eicosapentaenoic Acid in Human Colon Cancer (HT-29) Cells , 2008 .

[10]  A. Tsantili-Kakoulidou,et al.  Investigation of the lipophilic behaviour of some thiazolidinediones. Relationships with PPAR-gamma activity. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  J. Reichrath,et al.  Present concepts and future outlook: Function of peroxisome proliferator‐activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer , 2007, Journal of cellular physiology.

[12]  Y. Umezawa,et al.  A fluorescent indicator to visualize ligand-induced receptor/coactivator interactions for screening of peroxisome proliferator-activated receptor gamma ligands in living cells. , 2007, Biosensors & bioelectronics.

[13]  A. Bonvin,et al.  Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy. , 2007, Molecular endocrinology.

[14]  J. Roman,et al.  Peroxisome proliferator-activated receptor &ggr;: a novel target for cancer therapeutics? , 2007, Anti-cancer drugs.

[15]  M. Imran,et al.  Recent thiazolidinediones as antidiabetics , 2007 .

[16]  Arya M. Sharma,et al.  Can PPARgamma agonists have a role in the management of obesity-related hypertension? , 2006, Vascular pharmacology.

[17]  A. Lasaridis,et al.  Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect. , 2006, American journal of hypertension.

[18]  M. Belvisi,et al.  Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. , 2006, European journal of pharmacology.

[19]  Arnaud Pillon,et al.  Differential responses of PPARα, PPARδ, and PPARγ reporter cell lines to selective PPAR synthetic ligands , 2005 .

[20]  Matej Oresic,et al.  The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-gamma2 isoform. , 2005, Diabetes.

[21]  T. Itoh,et al.  Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents. , 2005, Bioorganic & medicinal chemistry letters.

[22]  Hualiang Jiang,et al.  A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist. , 2004, Analytical biochemistry.

[23]  Abraham Brouwer,et al.  Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[24]  T. Kurtz,et al.  α-Lipoic acid-based PPARγ agonists for treating inflammatory skin diseases , 2004, Archives of Dermatological Research.

[25]  T. Leff,et al.  Review: Peroxisome Proliferator-Activated Receptor-γ and Its Role in the Development and Treatment of Diabetes , 2004, Experimental diabesity research.

[26]  J. Fleckner,et al.  Prediction of PPAR-α ligand-mediated physiological changes using gene expression profiles Published, JLR Papers in Press, December 16, 2003. DOI 10.1194/jlr.M300239-JLR200 , 2004, Journal of Lipid Research.

[27]  A. Dobrian,et al.  Pioglitazone Prevents Hypertension and Reduces Oxidative Stress in Diet-Induced Obesity , 2004, Hypertension.

[28]  B. Staels,et al.  Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[29]  T. Willson,et al.  Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)—synthesis and biological activity , 2003 .

[30]  Minghan Wang,et al.  Modulation of PPARγ activity with pharmaceutical agents: Treatment of insulin resistance and atherosclerosis , 2003, Journal of cellular biochemistry.

[31]  B. Spiegelman,et al.  Genetic Analysis of Adipogenesis through Peroxisome Proliferator-activated Receptor γ Isoforms* , 2002, The Journal of Biological Chemistry.

[32]  Yang Li,et al.  T0070907, a Selective Ligand for Peroxisome Proliferator-activated Receptor γ, Functions as an Antagonist of Biochemical and Cellular Activities* , 2002, The Journal of Biological Chemistry.

[33]  T. Willson,et al.  Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. , 2002, Biochemistry.

[34]  P. Picci,et al.  Troglitazione affects survival of human osteosarcoma cells , 2002, International journal of cancer.

[35]  Á. Pascual,et al.  Nuclear hormone receptors and gene expression. , 2001, Physiological reviews.

[36]  S. Kliewer,et al.  A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[37]  B. van der Burg,et al.  4-Hydroxytamoxifen Trans-Represses Nuclear Factor-κB Activity in Human Osteoblastic U2-OS Cells through Estrogen Receptor (ER)α, and Not through ERβ. , 2001, Endocrinology.

[38]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[39]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[40]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. , 1999, Current opinion in biotechnology.

[41]  K. Chien,et al.  PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .

[42]  M. Lazar,et al.  A Potent Antidiabetic Thiazolidinedione with Unique Peroxisome Proliferator-activated Receptor γ-activating Properties* , 1998, The Journal of Biological Chemistry.

[43]  J. Lehmann,et al.  N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. , 1998, Journal of medicinal chemistry.

[44]  B. van der Burg,et al.  Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[45]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.

[46]  J. Holder,et al.  Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. , 1998, The Journal of pharmacology and experimental therapeutics.

[47]  G. Struhl,et al.  Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb , 1998, Nature.

[48]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[49]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[50]  J. Flier,et al.  Ligand-independent Activation Domain in the N Terminus of Peroxisome Proliferator-activated Receptor γ (PPARγ) , 1997, The Journal of Biological Chemistry.

[51]  J. Auwerx,et al.  The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* , 1997, The Journal of Biological Chemistry.

[52]  W. Wahli,et al.  Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. , 1997, Molecular endocrinology.

[53]  M. Jimenez-Linan,et al.  Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. , 1997, The Journal of clinical investigation.

[54]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[55]  W. Wahli,et al.  The PPARα–leukotriene B4 pathway to inflammation control , 1996, Nature.

[56]  M. D. Leibowitz,et al.  Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator Activated Receptors γ1 and γ2 , 1996 .

[57]  B. Spiegelman,et al.  Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. , 1996, The Journal of clinical investigation.

[58]  J. Lehmann,et al.  The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones , 1996 .

[59]  J. Lehmann,et al.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.

[60]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[61]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[62]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[63]  B. Spiegelman,et al.  mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.

[64]  A. Verma,et al.  The Direct Factor Xa Inhibitor Rivaroxaban , 2022 .

[65]  H. Gronemeyer,et al.  Synthesis of the PPARβ/δ-selective agonist GW501516 and C4-thiazole-substituted analogs , 2006 .

[66]  Béatrice Desvergne,et al.  Peroxisome-proliferator-activated receptors and cancers: complex stories , 2004, Nature Reviews Cancer.

[67]  A. Wolffe,et al.  PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis , 2002 .

[68]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.